45 citations
,
July 2025 in “Journal of Medicinal Chemistry” Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
1 citations
,
May 2008 in “Toxicon” The lowest effective dose of Botox for detrusor sphincter dyssynergia is between 75-100 units.
February 2021 in “Reactions Weekly” Finasteride and dutasteride may cause macular abnormalities.
January 2005 in “Translational and Clinical Pharmacology” HDMHG0401-10 improves hair loss in men with androgenetic alopecia and has no major side effects.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
September 2024 in “International Journal of Applied Pharmaceutics” A reliable method was developed to measure Finasteride and Tadalafil in rat blood.
14 citations
,
November 2011 in “Journal of The American Academy of Dermatology” Alopecia Areata Incognita causes widespread hair thinning, and treatment with systemic corticosteroids and psychiatric support can lead to remission.
22 citations
,
January 2018 in “European urology focus” New drugs and combination therapies are improving treatment for lower urinary tract symptoms.
23 citations
,
January 2021 in “Biomedicine & Pharmacotherapy” DHT stops hair regrowth in mice, similar to human hair loss.
April 2023 in “Journal of Investigative Dermatology” cp-asiAR may effectively treat hair loss by targeting androgen receptors.
August 2016 in “Journal of Investigative Dermatology” Dutasteride improved hair density and thickness in men not helped by finasteride, with minimal side effects.
April 2025 in “Pharmaceuticals” APA is a promising new compound for repairing damaged hair, outperforming Olaplex® in strength and elasticity.
December 2024 in “Journal of Cancer Therapy and Research” Artocarpus heterophyllus seed extract may help treat prostate inflammation without side effects.
7 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism”
September 2024 in “Cureus” A new method improves platelet testing for heart disease patients.
18 citations
,
February 2014 in “PubMed” Androgenetic alopecia is a common hair loss condition caused by testosterone effects on hair follicles, leading to thinner, shorter, and less pigmented hair, diagnosed using scalp dermoscopy and treated with topical minoxidil, antiandrogen agents, and 5-alpha reductase inhibitors.
2 citations
,
December 2021 in “Korean Journal of Clinical Pharmacy”
May 2023 in “Frontiers in Endocrinology” Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.
June 2023 in “Value in Health” Alopecia areata treatments often cause headaches and infections, highlighting the need for safer options.
15 citations
,
June 2019 in “Journal of Neuroendocrinology” Isoallopregnanolone may be a safe and effective treatment for reducing tics in a mouse model of Tourette syndrome.
1 citations
,
January 2010 in “Endocrine abstracts” August 2018 in “Brock University Digital Repository (Brock University)” Adolescent male rats release more stress hormones than adults, and testosterone affects them differently.
January 2026 in “Clinical Chemistry and Laboratory Medicine (CCLM)” The procedure accurately measures 5-alpha-dihydrotestosterone in blood, useful for standard tests.
November 2025 in “British Journal of Dermatology” The guideline recommends personalized treatment for alopecia areata, including new oral medications and psychological support.
May 2025 in “Oxford Academix (Oxford)” Dermatology trainees lack standardized guidelines and education for treating testosterone-induced skin conditions in transmasculine individuals.
5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
4 citations
,
October 1988 in “Clinics in Dermatology” Dihydrotestosterone (DHT) is crucial for conditions like male-pattern baldness and acne, and measuring a byproduct, androstanediol glucuronide, is a better way to assess DHT's effects than DHT blood levels.
The conclusion is that a treatment called cp-asiAR can reduce hair loss and promote hair growth, making it a potential new therapy for androgenetic alopecia.
25 citations
,
April 2014 in “Journal of Scientific and Innovative Research” Tridax procumbens may help treat diabetes.